Novavax

$14.24
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.19 (+9.12%) As of 3:59 PM EDT today
+$1.19 (+9.12%) Today

Why Robinhood?

You can buy or sell Novavax and other stocks, options, ETFs, and crypto commission-free!

About NVAX

Novavax, Inc. Common Stock, also called Novavax, is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. Read More It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Employees
165
Headquarters
Gaithersburg, Maryland
Founded
1987
Market Cap
605.46M
Price-Earnings Ratio
Dividend Yield
Average Volume
9.33M
High Today
$14.47
Low Today
$12.87
Open Price
$13.34
Volume
6.32M
52 Week High
$17.71
52 Week Low
$3.54

Collections

NVAX News

ReutersMar 28

Edited Transcript of NVAX earnings conference call or presentation 11-Mar-20 8:30pm GMT

Q4 2019 Novavax Inc Earnings Call ROCKVILLE Mar 28, 2020 (Thomson StreetEvents) -- Edited Transcript of Novavax Inc earnings conference call or presentation We
296
BenzingaMar 24

Novavax Shares Rally On Flu Vaccine Study Results: What You Need To Know

Novavax, Inc. (NASDAQ: NVAX), which was in the news recently on account of its COVID-19 vaccine development program, is in the spotlight yet again Tuesday. Flu
1,631
ReutersMar 24

BRIEF-Novavax’ Nanoflu Achieves All Primary Endpoints In Phase 3 Clinical Trial

March 24 (Reuters) - Novavax Inc: * NOVAVAX’ NANOFLU ACHIEVES ALL PRIMARY ENDPOINTS IN PHASE 3 CLINICAL TRIAL * NOVAVAX INC - NOVAVAX TO SUBMIT A U.S. BLA UND
7,364

NVAX Earnings

-$1.69
-$1.13
-$0.56
$0.00
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Estimated
per share
Actual
Expected Apr 30, After Hours

People Also Bought

You May Also Like

More NVAX News

MarketWatchMar 24

Novavax's stock rockets after late-stage trial for flu treatment achieves primary endpoints

Shares of Novavax Inc. NVAX, +30.66% rocketed 37% in premarket trading Tuesday, after the biotechnology company said its NanoFlu treatment for seasonal flu achi
492
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.